11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The Role of Opioids in Patients With Chronic Obstructive Pulmonary Disease and Chronic Breathlessness

      1 , 2
      JAMA Internal Medicine
      American Medical Association (AMA)

      Read this article at

      ScienceOpenPublisher
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: not found

          Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review.

          Patients with chronic obstructive pulmonary disease (COPD) commonly suffer from breathlessness, deconditioning, and reduced health-related quality of life (HRQL) despite best medical management. Opioids may relieve breathlessness at rest and on exertion in COPD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Regular, sustained-release morphine for chronic breathlessness: a multicentre, double-blind, randomised, placebo-controlled trial.

            Morphine may decrease the intensity of chronic breathlessness but data from a large randomised controlled trial (RCT) are lacking. This first, large, parallel-group trial aimed to test the efficacy and safety of regular, low-dose, sustained-release (SR) morphine compared with placebo for chronic breathlessness.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Opioids for chronic refractory breathlessness: patient predictors of beneficial response.

              Chronic refractory breathlessness is common and distressing in advanced disease. Despite level I evidence to support the use of opioids for this symptom, not all patients benefit. This study aimed to discover which patient characteristics predict those most likely to gain improvement in breathlessness. This is an international, multicentre, retrospective analysis of 213 individual pooled datasets from four clinical trials of an opioid for chronic refractory breathlessness. "Response to opioid" was defined as 1) an absolute value of ≥ 10 mm improvement on the visual analogue scale (VAS) and 2) a relative value of ≥ 10% improvement from baseline VAS. We investigated baseline predictors using logistic regression. In the final model, higher baseline breathlessness intensity scores strongly predicted absolute and relative response (p<0.001). Younger age also predicted relative response (p = 0.025); functional status and dominant cause of breathlessness did not. Some evidence supported the descriptor "not enough air", but was not statistically significant (p = 0.052). A therapeutic trial of opioids is appropriate, irrespective of the cause of the breathlessness or functional status. Younger people or those with worse breathlessness are more likely to benefit. Opioids have a role in the management of chronic refractory breathlessness, but net benefit for individuals must be optimised.
                Bookmark

                Author and article information

                Journal
                JAMA Internal Medicine
                JAMA Intern Med
                American Medical Association (AMA)
                2168-6106
                August 17 2020
                Affiliations
                [1 ]Division of Geriatrics, Department of Medicine, University of California, San Francisco
                [2 ]San Francisco Veterans Affairs Health Care System
                Article
                10.1001/jamainternmed.2020.3133
                f4bf2844-f2a7-443c-abbd-a7c25aaba61c
                © 2020
                History

                Comments

                Comment on this article